Palbociclib and neutropenia in metastatic breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial looks at why some patients with hormone-positive, HER2-negative metastatic breast cancer develop low white blood cells (neutropenia) when taking the drug palbociclib. It aims to find risk factors and check how well the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have breast cancer that has spread to other parts of the body (metastatic) and is hormone receptor-positive and HER2-negative.
- Your cancer is either new (de novo) or has come back after earlier treatment.
- You have not had any treatment for your metastatic breast cancer yet.
- You are well enough to be up and about at least half the day (ECOG score 0-2).
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well the drug Palbociclib works for Egyptian patients with metastatic breast cancer. It looks at how genes may affect treatment response.
This trial studies how well different doses of CDK4/6 inhibitors (palbociclib or ribociclib) work in people aged 65 or older with HR+/HER2- metastatic breast cancer. It aims to find the best starting dose to balance effectiveness and side effects.
This Phase 1 trial tests ribociclib plus belinostat in people with metastatic triple-negative breast cancer or recurrent ovarian cancer. It also looks at your tumor’s genetics (from a fresh biopsy) to see who might respond better.
This trial tests a drug called palbociclib for people with advanced liver cancer who have already tried at least two other treatments. The goal is to see if palbociclib can help shrink the cancer or slow its growth.
This study uses prescription records to learn about real-world use of palbociclib (a cancer medicine). You may be included if you’re an adult and have filled at least one palbociclib prescription.
This trial tests if Leucogen can prevent neutropenia (low white blood cells) caused by ribociclib, a targeted therapy for hormone receptor-positive, HER2-negative early breast cancer. It may help you stay on treatment without delays or dose reductions.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.